Boehringer Ingelheim grows in Italy, Boehringer Ingelheim Italy
Release Date: 2009-04-23
Even in 2008, Boehringer Ingelheim has continued its growth path following the objectives set at the beginning of the year.
Last year, net sales rose to 11.6 billion euros compared to 10.9 billion euros in 2007, an increase of 9.5% excluding foreign exchange effects and 5.9% in euro. For the 9th consecutive year the company, therefore, has grown more than the pharmaceutical market worldwide.
Prescription drugs for human use have significantly contributed to the overall result with a qratio of 79%.
Despite the deterioration of the exchange market and increased investment in Research and Development, the operating profit (comparable to EBIT) was at the level expected, and, with a balance of approximately 2 billion, has produced a solid return comparable than the previous year. In 2008 the incidence in operating profit compared to turnover was equal to 17.1%. With a balance of 1.4 billion euros, the profit after tax stood at a high level similar to that recorded last year, excluding the effects of extraordinary items charged in 2007.
Its HR has also experienced a positive growth with 1,500 more jobs in 2008 and a total of approximately 41,300 employees worldwide (+4% compared to 2007).
Overall, in fact, the company has invested 2.1 billion euros, in particular in the division of Prescription Drugs for Human Use, which has an investment in R & D amounted to 22% of net sales in the same division.
With a net turnover up to 503 million euros, an increase of 5.1% compared to last year, Italy is the sixth in the world market for the Boehringer Ingelheim group after the United States, Japan, Germany, Central Europe and Spain.
In particular, in the area of products for human health, the division of prescription drugs and hospital totaled over 307 million increase in net sales of 9.9% compared to 2007 and an increase of 3.3% in Division product of self and well being (65 million).
Growth in the veterinary division with sales of around 9 million euros (+13.6% compared to 2007).
"Boehringer Ingelheim Italy represents an important reality for the Group with a turnover against the time of economic crisis that is affecting many companies indiscriminately in the area, with results falling, cutting costs and the employment and termination the establishment or relocation of production in Eastern Europe - Sergio Daniotti precise, Country Manager of Boehringer Ingelheim Group in Italy - We are preparing, in fact, just this year to inaugurate a new production plant for active pharmaceutical ingredients in St. John Fornovo , in the province of Bergamo, which will, once fully operational, which employs around 200 staff. "
| Type: | NORMAL |
| Company: | Boehringer Ingelheim Italy |
| Country: | 意大利 |
| Url: | http://www.etribuna.com/aas/index.php?option=com_content&task=view&id=19118&Itemid=82 |